HUP0102535A2 - Új CD 19xCD3 specifikus polipeptidek és alkalmazásuk - Google Patents

Új CD 19xCD3 specifikus polipeptidek és alkalmazásuk

Info

Publication number
HUP0102535A2
HUP0102535A2 HU0102535A HUP0102535A HUP0102535A2 HU P0102535 A2 HUP0102535 A2 HU P0102535A2 HU 0102535 A HU0102535 A HU 0102535A HU P0102535 A HUP0102535 A HU P0102535A HU P0102535 A2 HUP0102535 A2 HU P0102535A2
Authority
HU
Hungary
Prior art keywords
polypeptides
polynucleotides
subject
vectors
aforementioned
Prior art date
Application number
HU0102535A
Other languages
English (en)
Inventor
Ralf Bargou
Peter Kufer
Ralf Lutterbüse
Anja Löffler
Original Assignee
Micromet Gesellschaft für biomedizinische Forschung mbH.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102535(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micromet Gesellschaft für biomedizinische Forschung mbH. filed Critical Micromet Gesellschaft für biomedizinische Forschung mbH.
Publication of HUP0102535A2 publication Critical patent/HUP0102535A2/hu
Publication of HUP0102535A3 publication Critical patent/HUP0102535A3/hu
Publication of HU229039B1 publication Critical patent/HU229039B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A találmány tárgyát új egyláncú multifunkciós polipeptidek képezik,amik legalább két kötőhelyet tartalmaznak a CD 19 és CD3 antigénekszámára. A találmány tárgyát képezik továbbá olyan polipeptidek,amikben az előzőkben említett polipeptid legalább még egy doménttartalmaz, aminek előnyösen egy előre meghatározott funkciója van.Emellett a találmány tárgyát képezik az említett polipeptideket kódolópolinukleotidok, valamint az említett polinukleotidokat tartalmazóvektorok és az ezekkel transzformált gazdasejtek, és ezekfelhasználása az említett polipeptidek előállításában. Emellett atalálmány tárgyát képezik azok a készítmények, előnyösen gyógyászatiés diagnosztikai készítmények, amik az előzőkben említettpolipeptidek, polinukleotidok és vektorok közül bármelyikettartalmazzák. A találmány tárgyát képezi továbbá az előzőkben említettpolipeptidek, polinukleotidok és vektorok használata immunterápiábanhasználható gyógyászati készítmények előállítására, előnyösenrosszindulatú B-sejtes szaporodás, azaz például nem-Hodgkin limfómaellen. Ó
HU0102535A 1998-04-21 1999-04-21 Cd19xcd3 specific polypeptides and uses thereof HU229039B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107269 1998-04-21
PCT/EP1999/002693 WO1999054440A1 (en) 1998-04-21 1999-04-21 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Publications (3)

Publication Number Publication Date
HUP0102535A2 true HUP0102535A2 (hu) 2001-10-28
HUP0102535A3 HUP0102535A3 (en) 2005-12-28
HU229039B1 HU229039B1 (en) 2013-07-29

Family

ID=8231795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102535A HU229039B1 (en) 1998-04-21 1999-04-21 Cd19xcd3 specific polypeptides and uses thereof

Country Status (29)

Country Link
US (2) US7112324B1 (hu)
EP (2) EP1071752B1 (hu)
JP (1) JP4169478B2 (hu)
KR (1) KR100508289B1 (hu)
CN (1) CN1302103C (hu)
AT (1) ATE244758T1 (hu)
AU (1) AU761587B2 (hu)
BR (1) BRPI9909860B8 (hu)
CA (1) CA2326389C (hu)
CU (1) CU23252B7 (hu)
CZ (1) CZ302070B6 (hu)
DE (1) DE69909459T2 (hu)
DK (1) DK1071752T3 (hu)
ES (1) ES2203141T3 (hu)
HK (1) HK1037674A1 (hu)
HR (1) HRP20000714B1 (hu)
HU (1) HU229039B1 (hu)
ID (1) ID27512A (hu)
IL (2) IL138857A0 (hu)
NO (1) NO326523B1 (hu)
NZ (1) NZ507381A (hu)
PL (1) PL199747B1 (hu)
PT (1) PT1071752E (hu)
RU (1) RU2228202C2 (hu)
SI (1) SI1071752T1 (hu)
SK (1) SK286683B6 (hu)
TR (1) TR200003087T2 (hu)
WO (1) WO1999054440A1 (hu)
ZA (1) ZA200005866B (hu)

Families Citing this family (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003087T2 (tr) * 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
CA2904259C (en) 1999-05-07 2016-11-15 Genentech, Inc. Use of rituximab to treat vasculitis
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP1543839B1 (en) * 1999-06-09 2017-09-20 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
RU2005141512A (ru) * 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
AU2004291026A1 (en) 2003-06-06 2005-06-02 Medimmune, Llc Use of EphA4 and modulator of EphA4 for diagnosis, treatment and prevention of cancer
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
BRPI0415457A (pt) * 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
EP2186527A1 (en) * 2003-11-28 2010-05-19 Micromet AG Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CA2555503C (en) * 2004-02-16 2018-03-27 Micromet Ag Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
PT1874819E (pt) 2005-04-18 2015-09-17 Amgen Res Munich Gmbh Neutralizadores de anticorpos do fator humano de estimulação de colónias de macrófagos e granulócitos
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
MY169746A (en) * 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
JP5686953B2 (ja) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
DK1976886T3 (en) * 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
NZ569204A (en) 2005-12-21 2012-03-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
JP5161798B2 (ja) * 2006-03-02 2013-03-13 アンチトープ リミテッド Ｔ細胞アッセイ
JP5825756B2 (ja) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
PL2520590T3 (pl) 2007-04-03 2019-02-28 Amgen Research (Munich) Gmbh Domena wiążąca wykazująca krzyżową swoistość gatunkową
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2691692C (en) 2007-07-09 2021-05-18 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
BRPI0814894A2 (pt) * 2007-07-31 2014-10-21 Lifescan Inc Diferenciação de células-tronco embrionárias de ser humano.
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
RU2476441C2 (ru) * 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
WO2010037835A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
HUE030090T2 (hu) 2008-10-01 2017-04-28 Amgen Res (Munich) Gmbh Fajok között specifikus PSMAxCD3 bispecifikus egyláncú ellenanyag
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
CN107184977A (zh) 2008-11-07 2017-09-22 安进研发（慕尼黑）股份有限公司 急性淋巴细胞白血病的治疗方法
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2012102021A (ru) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
HUE025759T2 (hu) 2009-10-27 2016-04-28 Amgen Res (Munich) Gmbh Dózisrendszer CD19xCD3 bispecifikus antitest adagolására
BR112012012983A2 (pt) 2009-12-04 2020-09-15 Genentech Inc método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
US20110165161A1 (en) * 2009-12-23 2011-07-07 Shih-Yao Lin Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
HUE030938T2 (hu) 2010-04-19 2017-06-28 Oryzon Genomics Sa Lizinspecifikus demetiláz-1 inhibitorok és alkalmazásuk
MA34291B1 (fr) 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
US8980933B2 (en) 2010-05-05 2015-03-17 Universitat Bayreuth Combretastatin analogs for use in the treatment of cancer
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
EP2598512A1 (en) 2010-07-28 2013-06-05 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
RU2611437C2 (ru) 2010-07-29 2017-02-22 Оризон Дженомикс С.А. Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
CA2815119C (en) 2010-10-27 2023-01-10 Amgen Research (Munich) Gmbh Means and methods for treating dlbcl
ES2842937T3 (es) 2010-11-10 2021-07-15 Amgen Res Munich Gmbh Prevención de efectos adversos provocados por dominios de unión específicos de CD3
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
CN103648529A (zh) 2011-04-28 2014-03-19 安进研发（慕尼黑）股份有限公司 用于给处于潜在不良反应的风险的患者施用CD19xCD3双特异性抗体的给药方案
MX369220B (es) 2011-05-21 2019-10-31 Macrogenics Inc Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
CA3137321A1 (en) * 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
DE202012012998U1 (de) 2011-08-31 2014-06-13 Daniel Elias Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MY187638A (en) 2011-10-20 2021-10-06 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
RS60920B1 (sr) 2011-11-07 2020-11-30 Medimmune Ltd Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CA2853138A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2817318A4 (en) 2012-02-22 2016-04-27 Univ Pennsylvania COMPOSITIONS AND METHOD FOR GENERATING A PERSISTENT POPULATION OF T CELLS FOR CANCER TREATMENT
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
ES2786263T3 (es) 2012-07-13 2020-10-09 Univ Pennsylvania Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN103965359B (zh) * 2013-01-24 2016-08-03 上海市肿瘤研究所 抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
EP2964241A1 (en) 2013-03-05 2016-01-13 Baylor College Of Medicine Oncolytic virus
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
RU2714733C2 (ru) * 2013-03-15 2020-02-19 Мемориал Слоан-Кеттеринг Кэнсер Сентер Технологии мультимеризации
US9561291B2 (en) * 2013-03-15 2017-02-07 Imre Kovesdi Methods of targeting T-cells to tumors
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970449B1 (en) 2013-03-15 2019-09-25 Amgen Research (Munich) GmbH Single chain binding molecules comprising n-terminal abp
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
CN107460201A (zh) * 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CN105408356A (zh) 2013-05-10 2016-03-16 努玛有限公司 双特异性构建体及其用于治疗多种疾病的用途
TR201904121T4 (tr) * 2013-07-09 2019-04-22 The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human İnsan bispesifik egfrviii antikoru birleştirme molekülleri.
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EP3620470B1 (en) 2013-10-11 2023-07-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
RU2577226C2 (ru) * 2014-04-10 2016-03-10 Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
RU2568910C2 (ru) * 2014-04-18 2015-11-20 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний
CN105017422A (zh) * 2014-04-30 2015-11-04 山东百因制药技术有限公司 一种抗cd3/抗cd19双特异性抗体及其应用
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
WO2015172341A1 (zh) * 2014-05-14 2015-11-19 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
WO2015181683A1 (en) 2014-05-30 2015-12-03 Amgen Research (Munich) Gmbh Risk-stratification of b-precursor acute lymphoblastic leukemia patients
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
EP3186237A1 (en) 2014-08-28 2017-07-05 Medizinische Universität Wien Heteroaromatic chalcone derivatives and their medical use
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
MA55043A (fr) 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
MA40801A1 (fr) 2015-01-23 2018-07-31 Sanofi Sa Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
WO2016135130A1 (en) 2015-02-23 2016-09-01 Serini Guido Non-natural semaphorins 3 and their medical use
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016138071A1 (en) 2015-02-24 2016-09-01 Short Jay M Conditionally active biological proteins
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
WO2016154003A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to gp120 and their use
US20180084766A1 (en) * 2015-04-07 2018-03-29 The Children's Medical Center Corporation Methods and compositions relating to an embryonic stem cell-based tumor model
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
WO2016170102A1 (en) 2015-04-22 2016-10-27 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3294768B1 (en) 2015-05-13 2019-08-21 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
AU2016260909B2 (en) 2015-05-13 2019-08-22 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
EA201792581A1 (ru) 2015-05-29 2018-07-31 Амфивена Терапьютикс, Инк. Способы применения биспецифических cd33- и cd3- связывающих белков
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN106349391A (zh) * 2015-07-17 2017-01-25 中国科学院深圳先进技术研究院 Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EA038329B1 (ru) 2015-08-28 2021-08-10 Амьюникс Фармасьютикалз, Инк. Химерный полипептидный комплекс и способы его получения и применения
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356407B1 (en) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
US10392441B2 (en) 2015-10-07 2019-08-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
MX2018005063A (es) 2015-11-02 2018-12-10 Bioatla Llc Polipéptidos condicionalmente activos.
AU2016349392B2 (en) 2015-11-03 2023-07-13 The Trustees Of Columbia University In The City Of New York Neutralizing antibodies to HIV-1 gp41 and their use
CN105296421B (zh) * 2015-11-24 2019-01-29 高岱清 一种双特异性抗体活化的t细胞及制备方法与应用
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
LT3386997T (lt) 2015-12-09 2021-12-10 Medizinische Universität Wien Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109311979A (zh) 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
DK3411402T3 (da) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
US10702518B2 (en) 2016-02-15 2020-07-07 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH TAF1 inhibitors for the therapy of cancer
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
SG11201808909WA (en) * 2016-04-13 2018-11-29 Vivia Biotech Sl Ex vivo bite-activated t cells
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CN105906720A (zh) * 2016-05-16 2016-08-31 武汉汉密顿生物科技股份有限公司 靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
KR102523402B1 (ko) 2016-06-14 2023-04-19 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
US10669338B2 (en) 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018057915A1 (en) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Engineered lymphocytes
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
AU2017359288A1 (en) 2016-11-14 2019-05-30 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
AU2017361846A1 (en) 2016-11-16 2019-05-30 Ablynx Nv T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
US11427633B2 (en) * 2016-12-13 2022-08-30 Crage Medical Co., Limited Anti-CD19 humanized antibody and immune effector cell targeting cd 19
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
CN108264566B (zh) * 2016-12-30 2021-05-14 惠和生物技术(上海)有限公司 一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
MX2019009848A (es) 2017-02-20 2019-12-19 Dragonfly Therapeutics Inc Proteínas que se unen a her2, nkg2d y cd16.
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
CN108659112B (zh) * 2017-03-30 2021-01-26 上海市同济医院 一种非对称双特异性抗体
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CA3059820A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
JP7474193B2 (ja) 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
BR112020002013B1 (pt) 2017-08-03 2023-01-24 Amgen Inc Muteínas de il-21, método de preparação das mesmas, ácido nucleico, vetor, célula hospedeira, kit, uso dos mesmos e composição farmacêutica
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
BR112020004543A2 (pt) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. proteínas de ligação ativadas condicionalmente restritas
CA3072600A1 (en) 2017-09-15 2019-03-21 Amgen Inc. Process for lyophilized pharmaceutical formulation of a therapeutic protein
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
KR20200068655A (ko) 2017-10-13 2020-06-15 머크 샤프 앤드 돔 코포레이션 미만성 거대 b 세포 림프종의 치료를 위한 조성물 및 방법
AU2018347607A1 (en) 2017-10-14 2020-03-26 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
AU2018358804A1 (en) 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
CN111315780A (zh) 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
CN111465618A (zh) 2017-12-12 2020-07-28 宏观基因有限公司 双特异性cd16-结合分子及其在疾病治疗中的用途
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3724223A1 (en) 2018-01-02 2020-10-21 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN107987169B (zh) * 2018-01-05 2021-10-08 阿思科力(苏州)生物科技有限公司 一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
CA3087273A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
CN112368012A (zh) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 靶向nkg2d受体的抗体可变结构域
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
CN111971299A (zh) 2018-02-21 2020-11-20 美国政府(由卫生和人类服务部的部长所代表) HIV-1 Env的中和抗体及其用途
WO2019166650A1 (en) 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
US20210113594A1 (en) * 2018-03-13 2021-04-22 Osaka University Tumor immunomodulator
WO2019183094A1 (en) 2018-03-19 2019-09-26 The Regents Of The University Of Michigan Compositions and methods for t-cell and cytokine activation
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
CA3099704A1 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112584859A (zh) 2018-07-02 2021-03-30 美国安进公司 抗steap1抗原结合蛋白
JP2021532140A (ja) 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
US20210284732A1 (en) 2018-07-31 2021-09-16 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
MA53330A (fr) 2018-08-03 2021-06-09 Amgen Inc Constructions d'anticorps pour cldn18.2 et cd3
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
US11066476B2 (en) 2018-09-14 2021-07-20 Shanghai tongji hospital Asymmetric bispecific antibody
CN110590955B (zh) * 2018-09-17 2021-05-18 北京盛诺基医药科技股份有限公司 一种双特异性抗体
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
UY38393A (es) 2018-09-28 2020-03-31 Amgen Inc Anticuerpos contra bcma soluble
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
JP2022512636A (ja) 2018-10-11 2022-02-07 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
CA3115296A1 (en) 2018-10-23 2020-04-30 Amgen Inc. Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
CA3119467A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
TW202043253A (zh) 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
US20220137010A1 (en) 2019-02-20 2022-05-05 Amgen Inc. Methods of determining protein stability
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
EP3934762A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
EP3948242A1 (en) 2019-03-27 2022-02-09 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
US20220204620A1 (en) 2019-04-30 2022-06-30 Amgen Research (Munich) Gmbh Means and methods for treating burkitt lymphoma or leukemia
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
MX2021015045A (es) 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
TW202045711A (zh) 2019-06-13 2020-12-16 美商安進公司 生物製品製造中基於生物量之自動灌注控制
US20220380474A1 (en) 2019-07-02 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Monoclonal antibodies that bind egfrviii and their use
CN110623921B (zh) * 2019-08-15 2020-10-30 北京东方百泰生物科技股份有限公司 一种抗cd3和抗cd19的双特异性抗体注射制剂
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
KR20220077140A (ko) 2019-10-02 2022-06-08 도메인 테라퓨틱스 프로스타글란딘 e2(pge2) ep4 수용체 길항제
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP4045142A1 (en) 2019-10-16 2022-08-24 CeMM - Forschungszentrum für Molekulare Medizin GmbH Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP3808741A1 (en) 2019-10-16 2021-04-21 CeMM - Forschungszentrum für Molekulare Medizin GmbH Compounds for targeted degradation of carrier proteins and uses thereof
TW202132340A (zh) 2019-11-04 2021-09-01 美商安進公司 治療白血病之方法
EP3819312A1 (en) 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN115697388A (zh) 2020-01-30 2023-02-03 优莫佳生物制药股份有限公司 双特异性转导增强子
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
TW202140561A (zh) 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
WO2021170071A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
CN115066440A (zh) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20220017636A1 (en) 2020-05-19 2022-01-20 Amgen Inc. Mageb2 binding constructs
TW202210101A (zh) 2020-05-29 2022-03-16 美商安進公司 與ｃｄ３３和ｃｄ３結合的雙特異性構建體的減輕不良反應投與
CA3185858A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
JP2023536461A (ja) 2020-07-29 2023-08-25 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
IL300764A (en) 2020-08-27 2023-04-01 Juntendo Educational Found Antibody and composition of calr-cd3 mutant anti-clotting drugs
JP2023541845A (ja) 2020-09-11 2023-10-04 アムジエン・インコーポレーテツド タンパク質凝集を減少させる材料及び方法
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
JP2023545588A (ja) 2020-10-16 2023-10-30 ツェーエムエム－フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
KR20230104229A (ko) 2020-11-06 2023-07-07 암젠 인크 Cd3에 결합하는 폴리펩티드 구축물
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
EP4240768A2 (en) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
TW202233682A (zh) 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
MX2023006573A (es) 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
US20240101717A1 (en) 2021-01-22 2024-03-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
KR20230142790A (ko) 2021-02-09 2023-10-11 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
EP4292596A1 (en) 2021-02-10 2023-12-20 Curon Biopharmaceutical (Shanghai) Co., Limited Method and combination for treating tumors
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US20240075406A1 (en) 2021-03-10 2024-03-07 Amgen Inc. Parallel chromatography systems and methods
CN117043173A (zh) 2021-03-10 2023-11-10 美国安进公司 重组蛋白的纯化方法
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
CA3232223A1 (en) 2021-09-17 2023-03-23 Ying Fu Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CA3235228A1 (en) 2021-10-15 2023-04-20 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engagers
WO2023076318A1 (en) 2021-10-27 2023-05-04 Amgen Inc. Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
EP4180035A1 (en) 2021-11-15 2023-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023164474A1 (en) 2022-02-23 2023-08-31 Amgen Inc. Cancer treatment targeting dll3
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023237366A1 (en) 2022-05-27 2023-12-14 Sanofi Anti-bcma antibodies
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2063035A1 (en) * 1991-03-27 1992-09-28 Klaus Karjalainen Chimaeric antibodies containing the ligand domain of cd4
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
EP0835134A1 (en) 1995-05-17 1998-04-15 Regents Of The University Of Minnesota Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
TR200003087T2 (tr) 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками

Also Published As

Publication number Publication date
ATE244758T1 (de) 2003-07-15
BRPI9909860B1 (pt) 2016-05-31
CZ302070B6 (cs) 2010-09-29
US7575923B2 (en) 2009-08-18
HUP0102535A3 (en) 2005-12-28
SK286683B6 (sk) 2009-03-05
SI1071752T1 (en) 2003-12-31
ZA200005866B (en) 2001-04-18
SK15792000A3 (sk) 2001-05-10
BRPI9909860B8 (pt) 2021-05-25
CN1302103C (zh) 2007-02-28
CZ20003889A3 (cs) 2001-03-14
EP1071752B1 (en) 2003-07-09
PL344016A1 (en) 2001-09-24
EP1071752A1 (en) 2001-01-31
TR200003087T2 (tr) 2001-02-21
NZ507381A (en) 2003-12-19
RU2228202C2 (ru) 2004-05-10
CA2326389C (en) 2007-01-23
IL138857A (en) 2007-08-19
NO20005296L (no) 2000-12-13
PL199747B1 (pl) 2008-10-31
ES2203141T3 (es) 2004-04-01
WO1999054440A1 (en) 1999-10-28
DE69909459T2 (de) 2004-05-27
EP1348715A2 (en) 2003-10-01
CA2326389A1 (en) 1999-10-28
NO326523B1 (no) 2008-12-22
JP2002512020A (ja) 2002-04-23
KR20010071150A (ko) 2001-07-28
NO20005296D0 (no) 2000-10-20
PT1071752E (pt) 2003-11-28
US7112324B1 (en) 2006-09-26
CU23252B7 (es) 2007-12-17
EP1348715A3 (en) 2003-11-19
ID27512A (id) 2001-04-12
US20060193852A1 (en) 2006-08-31
HK1037674A1 (en) 2002-02-15
HRP20000714B1 (en) 2006-03-31
AU4135299A (en) 1999-11-08
KR100508289B1 (ko) 2005-08-17
BR9909860A (pt) 2000-12-19
JP4169478B2 (ja) 2008-10-22
AU761587B2 (en) 2003-06-05
DE69909459D1 (de) 2003-08-14
CN1299410A (zh) 2001-06-13
IL138857A0 (en) 2001-10-31
DK1071752T3 (da) 2003-10-20
HRP20000714A2 (en) 2001-12-31
HU229039B1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
HUP0102535A2 (hu) Új CD 19xCD3 specifikus polipeptidek és alkalmazásuk
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
HUP0102005A2 (hu) CD23 elleni antitestek, ezek származékai, és gyógyászati alkalmazásuk
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
GR3026219T3 (en) Mouse monoclonal antibodies
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
DE69433406D1 (de) Antikörper gegen cd40
ATE544776T1 (de) Chimäre dna-bindeproteine
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
EP0739350A4 (en) LIGAND FIXING FAS ANTIGEN
TW272197B (hu)
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
SI1027375T1 (sl) Anti-idiotipska monoklonska protitelesa, njihova uporaba v aktivni imunoterapiji malignih tumorjev in sestavki, ki jih vsebujejo
AU2003204088A1 (en) Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them
AU622548B2 (en) Novel tumor-associated antigen, antibodies, compositions and uses therefor
WO2000071573A3 (en) Immunogenic peptides derived from mage and the use thereof

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): IFJ. SZENTPETERI ADAM, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: S.B.G. & K. SZABADALMI ES UEGYVEDI IRODAK, HU

GB9A Succession in title

Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE

Free format text: FORMER OWNER(S): MICROMET GESELLSCHAFT FUER BIOMEDIZINISCHE FORSCHUNG MBH., DE; MICROMET AG, DE; MICROMET AG, DE; MICROMET GMBH, DE

HC9A Change of name, address

Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE

Free format text: FORMER OWNER(S): MICROMET GESELLSCHAFT FUER BIOMEDIZINISCHE FORSCHUNG MBH., DE; MICROMET AG, DE; MICROMET AG, DE; MICROMET GMBH, DE